Donepezil/solifenacin

Drug Profile

Donepezil/solifenacin

Alternative Names: Cognicept; CPC-201

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chase Pharmaceuticals
  • Class Antidementias; Antispasmodics; Esters; Indans; Isoquinolines; Nootropics; Piperidines; Quinuclidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Dementia

Most Recent Events

  • 08 Aug 2017 Chase Pharmaceuticals withdraws a phase II study prior to enrolment for Dementia of Alzheimer's type in USA (NCT02860065)
  • 01 Dec 2016 Chase Pharmaceuticals completes a phase II extension trial for Alzheimers disease in USA (NCT02434666)
  • 22 Nov 2016 Chase Pharmaceuticals has been acquired by Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top